A major milestone has just been reached for people living with focal segmental glomerulosclerosis (FSGS)—a rare and serious kidney disease.

For the first time, the U.S. Food and Drug Administration (FDA) has approved a medication specifically to treat FSGS. This marks a long-awaited breakthrough for patients and families who have had limited treatment options for decades.*

But what does this actually mean for you or your loved one? Let’s break it down.

What Is FSGS?

FSGS is a disease that affects the filters in your kidneys (called glomeruli). Over time, these filters become scarred, making it harder for your kidneys to do their job.

Common effects of FSGS include:

• Protein leaking into your urine (proteinuria)
• Swelling in different parts of the body
• Reduced kidney function over time

FSGS can progress slowly or quickly, and in some cases, it may lead to kidney failure.

Why This Approval Is a Big Deal

Until now, there has been no FDA-approved treatment specifically for FSGS. Doctors have often relied on steroids, blood pressure medications and other off-label therapies.

While these treatments can help, they don’t work for everyone, and some come with significant side effects.

This new approval changes that.

👉 It gives doctors a targeted treatment option
👉 It aligns with current clinical guidelines for managing kidney disease
👉 It offers new hope for patients who haven’t responded to existing therapies

What Is the New Medication?

The newly approved medication is called FILSPARI® (sparsentan). It is approved for:

• Adults and children (age 8 and older)
• People with FSGS who do not have nephrotic syndrome

This expands its use beyond another kidney condition called IgA nephropathy (IgAN), where it was already being used.

How Does It Work?

FILSPARI works by targeting two key pathways involved in kidney damage:

• Endothelin A receptors
• Angiotensin II receptors

These pathways play a role in:

• Inflammation
• Scarring in the kidneys

By blocking both, the medication may help:

• Reduce damage to kidney filters
• Lower protein levels in the urine
• Slow disease progression

What Did the Research Show?

The approval is based on results from a large clinical study called the DUPLEX trial.

Results published in The New England Journal of Medicine showed that: 

• Patients taking FILSPARI saw a significant reduction in proteinuria
• Results were stronger compared to a commonly used medication (irbesartan)
• Benefits were especially noticeable in patients without nephrotic syndrome

Who Might Benefit From This Treatment?

This medication may be an option if you:

• Have been diagnosed with FSGS
• Do not currently have nephrotic syndrome
• Are working with a nephrologist to manage your condition

However, it’s not a one-size-fits-all solution.

Your doctor will consider:

• Your stage of kidney disease
• Other health conditions
• Medications you’re already taking

What This Means for the Future of CKD Care

This approval is about more than just one medication.

It signals a broader shift:

✔️ More attention on rare kidney diseases
✔️ More research into targeted therapies
✔️ More opportunities for patients to access better care

For many in the CKD community, this is a reminder that progress is happening—even if it sometimes feels slow.

What Should You Do Next?

If you or a loved one has FSGS, here are a few practical steps:

• Talk to your doctor: Ask if this treatment could be right for you
• Stay informed: New research and options continue to emerge
• Track your health: Keep an eye on symptoms and lab results
• Explore support resources: You don’t have to navigate this alone

Medical Review Note

This article was developed using publicly available information and reviewed for clarity and accuracy. It is not a substitute for professional medical advice. Always consult your healthcare provider about your specific condition and treatment options. This content is shared for informational purposes only, and Responsum Health does not receive any commercial benefit or compensation from Travere Therapeutics related to this information.

*Travere Therapeutics. (April 13, 2026) “Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS”. travere.com